Vimta Labs Ltd
NSE:VIMTALABS
Vimta Labs Ltd
Vimta Labs Ltd. engages in the provision of contract research and testing. The company is headquartered in Hyderabad, Telangana and currently employs 1,273 full-time employees. The Company’s business includes analytical, clinical, preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries. The firm provides services of testing and contract research in the fields of analytical food and water, preclinical research, clinical research, biopharma, environmental assessments and clinical reference lab. The company supports regulatory authorities in mandatory certification of food and agricultural products exported from India. The company assists the food industry for nutritional labelling, food safety evaluations, trace analysis and shelf life studies. Its environmental services include site selection and liability studies; environmental impact assessments; environment management plans and carrying capacity-based regional studies.
Vimta Labs Ltd. engages in the provision of contract research and testing. The company is headquartered in Hyderabad, Telangana and currently employs 1,273 full-time employees. The Company’s business includes analytical, clinical, preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries. The firm provides services of testing and contract research in the fields of analytical food and water, preclinical research, clinical research, biopharma, environmental assessments and clinical reference lab. The company supports regulatory authorities in mandatory certification of food and agricultural products exported from India. The company assists the food industry for nutritional labelling, food safety evaluations, trace analysis and shelf life studies. Its environmental services include site selection and liability studies; environmental impact assessments; environment management plans and carrying capacity-based regional studies.
Revenue Growth: Vimta Labs posted Q3 revenue of INR 100.5 crores, up 10.2% year-over-year, with pharmaceutical and food testing driving most of the growth.
Quarterly Dip: Revenue declined 3.9% sequentially due to operational delays and deferred bookings, but management expects a stronger Q4.
Profitability: EBITDA and PAT both grew slightly year-over-year, maintaining high EBITDA margins at 34.3% and PAT margin at 17.5%.
Full Year Target: The company acknowledges the INR 500 crore annual revenue goal may not be fully met this year, but remains confident in a strong finish and maintains this target for next year.
Biologics Launch: Biologics contract research services are on track for commercialization in Q1 next fiscal, with initial focus on building client relationships.
Export Momentum: Export revenues rose to 39% of total, with around 60% of exports going to the US.
Margins & Cost: High EBITDA margins are expected to continue, with efficiency gains offsetting cost escalation in manpower and inputs.
CapEx & ROCE: CapEx has increased due to expansion and new services; ROCE dipped temporarily but is expected to recover as new divisions contribute.
